http://www.washingtonpost.com/wp-dyn/articles/A19781-2005Feb12.html

U.S. Denies Patent for a Too-Human Hybrid

Scientist Sought Legal Precedent to Keep Others From Profiting From 
Similar 'Inventions'

By Rick Weiss

Washington Post Staff Writer

Sunday, February 13, 2005; Page A03

A New York scientist's seven-year effort to win a patent on a 
laboratory-conceived creature that is part human and part animal 
ended in failure Friday, closing a historic and somewhat ghoulish 
chapter in American intellectual-property law.

The U.S. Patent and Trademark Office rejected the claim, saying the 
hybrid -- designed for use in medical research but not yet created -- 
would be too closely related to a human to be patentable.

Paradoxically, the rejection was a victory of sorts for the inventor, 
Stuart Newman of New York Medical College in Valhalla, N.Y. An 
opponent of patents on living things, he had no intention of making 
the creatures. His goal was to set a legal precedent that would keep 
others from profiting from any similar "inventions."

But in an age when science is increasingly melding human and animal 
components for research -- already the government has allowed many 
patents on "humanized" animals, including a mouse with a human immune 
system -- the decision leaves a crucial question unanswered: At what 
point is something too human to patent?

Officials said it was not so difficult to make the call this time 
because Newman's technique could easily have created something that 
was much more person than not. But newer methods are allowing 
scientists to fine-tune those percentages, putting the patent office 
in an awkward position of being the federal arbiter of what is human.

"I don't think anyone knows in terms of crude percentages how to 
differentiate between humans and nonhumans," said John Doll, a deputy 
commissioner for patents. Yet neither is the office comfortable with 
a "we'll know it when we see it" approach, he added: "It would be 
very helpful . . . to have some guidance from Congress or the courts."

The Newman case reveals how far U.S. intellectual-property law has 
lagged behind the art and science of biotechnology. The Supreme Court 
has addressed the issue of patenting life only once, and that was 25 
years ago.

It also raises profound questions about the differences -- and 
similarities -- between humans and other animals, and the limits of 
treating animals as property.

"The whole privatization of the biological world has to be looked 
at," Newman said, "so we don't suddenly all find ourselves in the 
position of saying, 'How did we get here? Everything is owned.' "

Newman's application, filed in 1997, described a technique for 
combining human embryo cells with cells from the embryo of a monkey, 
ape or other animal to create a blend of the two -- what scientists 
call a chimera. That's the Greek term for the mythological creature 
that had a lion's head, a goat's body and a serpent's tail.

Others had used similar methods to create a "geep," part goat and 
part sheep. But Newman's human-animal chimeras would have greater 
utility in medicine, for drug and toxicity testing and perhaps as 
sources of organs for transplantation into people.

In collaboration with Jeremy Rifkin, a Washington biotech activist 
and president of the Foundation on Economic Trends, he challenged the 
patent office: Issue the patent, which would keep others from 
pursuing such work for 20 years, or reject it, effectively 
accomplishing the same thing.

The two had until Friday to appeal the latest rejection, but they 
decided to let it pass and declare victory.

For Rifkin, the case was deja vu in reverse. When U.S. scientist 
Ananda Chakrabarty applied for the first patent on a living organism 
-- a genetically engineered bacterium able to digest oil spills -- 
the case ended up in the Supreme Court because the patent office did 
not want to patent life forms. That time Rifkin filed the main amicus 
brief supporting the patent office.

They lost. In a 5 to 4 decision, the court declared that patents 
could be issued on "anything under the sun that is made by man."

The office has obliged, issuing patents on bacteria, yeast and, as of 
last fall, 436 animals.

In 1987, the patent office announced it would draw the line with 
humans, but it offered no legal rationale or statutory backing.

The paper trail created by the Newman claim offers perhaps the best 
explication yet for that ban. One rationale in the documents sent to 
Newman is that such a patent would be "inconsistent with the 
constitutional right to privacy." After all, the office wrote, a 
patent allows the owner to exclude others from making the claimed 
invention. If a patent were to issue on a human, it would conflict 
with one of the Constitution's core privacy rights -- a person's 
right to decide whether and when to procreate.

Patents on humans could also conflict with the 13th Amendment's 
prohibition against slavery. That is because a patent permits the 
owner to exclude others from "using" the invention. Because "use" can 
mean "employ," officials wrote, a patent holder could prevent a 
person from being employed by any other -- which "would be tantamount 
to involuntary servitude."

Finally, the office noted that it is illegal to import products that 
are made abroad using processes patented in the United States. To 
show how that could cause a problem in a world where people are 
patentable, it gave an example in which a person goes overseas and 
undergoes one of the many surgical procedures patented by U.S. 
doctors. Simply by returning to the United States, the office said, 
that "surgically altered human being" could be guilty of patent 
infringement for illegally importing herself.

Not all those concepts hold water with legal scholars. But the 
general position was greatly strengthened two years ago when Rep. 
David Joseph Weldon (R-Fla.) added a rider to an appropriations bill 
-- renewed this year -- barring patents on humans or human embryos.

Still unresolved by that wording, however, is what is human and what is not.

Last week, patent officials conceded they lack a good way of defining 
the "human" that Newman's patent supposedly too closely resembles.

The decision letter to Newman notes that many people have heart 
valves from pigs. A patent has even issued on the use of baboon cells 
in people to aid in organ transplantation. Those procedures, the 
letter says, "did not convert the human patient to a non-human."

Similarly, mice that have up to 1 percent human brain cells in their 
skulls are clearly mice, said Stanford University biologist Irving 
Weissman, one of the scientists who helped make hybrid rodents.

The tricky part, all agree, is what to do with the middle ground. 
Weissman and others, for example, have talked about their desire to 
make mice whose brains are made entirely of human brain cells.

Hank Greely, a professor of law and director of Stanford's Center for 
Law and the Biosciences, said even those animals would not seem very 
human to him. "But a chimp brain with human neurons. . . ."

That's exactly the kind of scenario that makes Rifkin, Newman and 
others want a total ban.

"If the U.S. Congress and president are not willing to do this now, 
then there is no door that will remain closed to an era of commercial 
eugenics," Rifkin said. "We'll be on our way to that brave new world 
that Aldous Huxley warned us about."

Leon Kass, chairman of the President's Council on Bioethics, agreed 
that Congress should at least get involved.

"The patent office is not the place for society to make its moral 
decisions," Kass said.

Weldon, the Florida representative, said he is interested in 
providing such guidance -- and believes the public would favor 
restrictions.

"There's instant public revulsion when you start talking with the 
average person about this stuff." For starters, Weldon said, "I'd 
like to ban the creation of human embryos with animal genes in them."

But many scientists fear that Congress is likely to overreact.

"There are chimeras out there that serve very valuable purposes in 
medical research, such as mice that make human antibodies," said 
Michael Werner, chief of policy for the Biotechnology Industry 
Organization. "This is sufficiently technical scientifically that it 
should be left to scientific bodies like the National Academy of 
Sciences to decide."

That organization is now preparing a report, due in April, that will 
address scientific and ethical issues relating to human-animal 
chimeras. And although it will not probe deeply into 
intellectual-property issues, it may at least offer the patent office 
-- and the nation -- a modicum of the guidance it craves.

Researcher Lucy Shackelford contributed to this report.


>Hi Keith ;
>
>Fascinating article on this subject. But it is dated 1999, any idea 
>of any progress that has been made?
>
>http://www.organicconsumers.org/Patent/rifikinhc.cfm
>
>US Human/Chimpanzee Life Form Patent Challenge by
>Jeremy Rifkin & Stuart Newman Will Now Go to the Federal Courts
>
>U.S. Ruling Aids Opponent Of Patents for Life Forms
>By Rick Weiss
>Washington Post Staff Writer
>Thursday, June 17, 1999; Page A2
>
>The U.S. Patent and Trademark Office has turned down a scientist's
>controversial request for a patent on creatures that would be part animal and
>part human--bizarre life forms that no one has made before, but that might
>prove useful in medical experiments.
>
>But unlike most patent office rejectees, the scientist, Stuart Newman, is
>celebrating. The New York Medical College biology professor never intended to
>make the animal-human hybrids. He applied for the patent to gain the legal
>standing to challenge U.S. patent policy, which allows patents on living
>entities.
>
>The patent office ruled in part that Newman's invention is too human to be
>patentable. By doing so, it opened the door to a series of legal challenges
>available to all patent applicants--a path that could lead to the Supreme
>Court.
>
>Newman hopes his appeals will force a judicial and congressional reassessment
>of the nation's 19-year-old policy of granting patents on life forms. That
>policy, based on a single court decision, has provided the foundation for
>today's $13 billion biotechnology industry.
>
>Some patent experts this week criticized Newman for "abusing" the federal
>patent review system to bypass the legal avenues by which patent law is
>normally made and changed. But even some critics confirmed that the strategy
>appeared to be working.
>
>In particular, said John Barton, a patent specialist at the Stanford
>University School of Law, the ploy has forced the patent office to
>acknowledge the relatively thin legal ice upon which its policies on life
>patents rest. The ruling also reveals the agency's apparent uncertainty about
>just how human a creature must be before it is no longer patentable, Barton
>and others said.
>
>The patent office has argued that to grant patents on people would violate
>the 13th Amendment to the Constitution, which abolished slavery. But neither
>the patent office nor Congress has ever defined "human."
>
>That question is of more than philosophical import today. Already, several
>patents have been allowed on animals containing human genes or organs. And
>just this week, scientists in Massachusetts said they were creating live
>embryos by combining cow and human cells.
>
>"When we applied for this patent a year and half ago, people reacted to it as
>if it was some kind of science fiction scenario," Newman said. "Developments
>in the past year have shown that similar things are already on the table and
>being considered seriously."
>
>In its rejection letter, the patent office says Newman's invention "embraces"
>a human being, but it does not say why other creatures with human components
>do not "embrace" a human being, said Washington patent attorney Patrick
>Coyne, who filed Newman's application.
>
>"This puts a big question mark on all commercial interests involving human
>embryos and embryonic . . . cells," said biotechnology activist Jeremy
>Rifkin, a co-applicant on Newman's claim, who has rallied religious leaders
>against patents on life forms.
>
>The agency concedes in its letter that in the Supreme Court's single foray
>into the topic--a 5 to 4 decision in 1980 allowing a patent on a microbe--the
>justices did not include humans on their list of nonpatentable life forms.
>But Stephen Kunin, the patent office's deputy assistant commissioner for
>patent policy, said the agency "believes" that Congress did not intend to
>allow patents on humans or on creatures that are essentially human when it
>passed the National Patent Act in 1956. The agency, however, offers no basis
>for that belief, Coyne said.
>
>Biotechnology executives have said that without access to patents on
>gene-altered animals and other living entities, they would not make the
>investments needed to develop new drugs and other products. Yesterday, some
>criticized Newman's legal attack.
>
>"The net outcome of this attempt may hurt valuable medical research and
>ultimately deny therapies for patients who need them," said Carl Feldbaum,
>president of the Biotechnology Industry Organization.
>
>Undaunted, Newman yesterday filed an appeal to the patent office.
>
>"Private ownership of inventions is not the only way progress has been made
>in the history of science and the history of medicine," Newman said.
>
>
>
>
>      
>
>_______________________________________________
>Biofuel mailing list
>Biofuel@sustainablelists.org
>http://sustainablelists.org/mailman/listinfo/sustainablelorgbiofuel
>
>Biofuel at Journey to Forever:
>http://journeytoforever.org/biofuel.html
>
>Search the combined Biofuel and Biofuels-biz list archives (70,000 messages):
>http://www.mail-archive.com/biofuel@sustainablelists.org/


_______________________________________________
Biofuel mailing list
Biofuel@sustainablelists.org
http://sustainablelists.org/mailman/listinfo/sustainablelorgbiofuel

Biofuel at Journey to Forever:
http://journeytoforever.org/biofuel.html

Search the combined Biofuel and Biofuels-biz list archives (70,000 messages):
http://www.mail-archive.com/biofuel@sustainablelists.org/

Reply via email to